Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy by Simmons, B. B. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Family & Community Medicine
Faculty Papers Department of Family & Community Medicine
Fall 11-2008
Angioedema after local trauma in a patient on
angiotensin-converting enzyme inhibitor therapy
B. B. Simmons
Temple University
Michelle A. Folsom
Calvert Family Practice Associates
L.eslie A. Bryden
Oregon Health and Science University
James Studdiford
Thomas Jefferson University, james.studdiford@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/fmfp
Part of the Family Medicine Commons, and the Translational Medical Research Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Family & Community Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Simmons, B. B.; Folsom, Michelle A.; Bryden, L.eslie A.; and Studdiford, James, "Angioedema after
local trauma in a patient on angiotensin-converting enzyme inhibitor therapy" (2008). Department of
Family & Community Medicine Faculty Papers. Paper 15.
http://jdc.jefferson.edu/fmfp/15
BRIEF REPORT
Angioedema After Local Trauma in a Patient on
Angiotensin-Converting Enzyme Inhibitor Therapy
B. Brent Simmons, MD, Michelle A. Folsom, MD, Leslie A. Bryden, MD, and
James S. Studdiford, MD, FACP
Angioedema is a side effect that is often associated with the use of angiotensin-converting enzyme (ACE)
inhibitor medications. These medications result in increased levels of circulating bradykinins. This case
illustrates the result of a local traumatic event to the upper lip, presumably causing marked bradykinin
release in a patient who was taking an ACE inhibitor. The local release of bradykinin from trauma, in
addition to decreased bradykinin catabolism secondary to ACE inhibitor therapy, resulted in angio-
edema predominantly in the upper lip. The angioedema resolved with discontinuation of the ACE inhibi-
tor. (J Am Board Fam Med 2008;21:577–9.)
As the indications and usage of angiotensin-con-
verting enzyme (ACE) inhibitor therapy increases,
one of its potential side effects, angioedema, is
becoming commonly encountered in primary care.
Angioedema is a potentially life-threatening side
effect of ACE inhibitor therapy, which has an es-
timated incidence of 0.1% up to 6%.1 Angioedema
resulting secondary to ACE inhibitor use may oc-
cur many years after therapy has been initiated.
However, it most often occurs within the ﬁrst week
after starting therapy.2 Up to 25% of reported cases
of angioedema seem to be a result of ACE inhibitor
therapy.2 The other most common causes include
allergic reactions, hereditary angioedema, C1 es-
terase inhibitor deﬁciency, and idiopathic angio-
edema.2
The mechanism of action of ACE inhibitors
includes the blockade of the ACE, which leads to
vasodilation. Other actions of ACE inhibitors in-
clude blockade of the conversion of substance P to
inactive peptides and the blockade of bradykinin
degradation. The increase in circulating substance
P and bradykinin, histamine release, and other
mechanisms lead to vasodilatation and increased
vascular permeability.1–3 Angioedema does not re-
semble other forms of edema in that it does not
appear in dependent areas and is often very tran-
sient and localized.4 The most important risk factor
for developing ACE inhibitor angioedema seems to
be African-American race. The mechanism of this
increased risk is not clear but may include brady-
kinin metabolism. Other risk factors include his-
tory of angioedema, allergies to seafood, and recent
head or neck surgery.2
Case
A 35-year-old African-American woman with a his-
tory of hypertension, well controlled (per outpa-
tient chart) with hydrochlorothiazide and lisinopril,
presented to the emergency department with a
markedly swollen upper lip and a sensation of chest
tightness and throat tightness (Figure 1). Lisinopril
was started approximately 1 year before this emer-
gency department visit. On the evening before ad-
mission, the patient bit her upper lip with moderate
force. Shortly thereafter she noted that her lip was
markedly swollen. The following morning she saw
her primary care physician. Because of continued
severe upper lip swelling and persistent feeling of
shortness of breath and “throat tightness,” she was
sent from her primary care physician’s ofﬁce to the
emergency department. She denied any recent in-
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sect bites; consumption of food precipitants (ba-
nanas, shrimp, peas, grapes, etc); illicit drug use;
herbal medications; and food or drug allergies.
Her medical history was signiﬁcant only for hy-
pertension. She had no history of angioedema.
Medications consisted of hydrochlorothiazide 25
mg daily, lisinopril 20 mg daily, and an etono-
gestrel/ethinyl estradiol vaginal ring. There had
not been any recent medication changes. Family
history was signiﬁcant for hypertension and diabe-
tes mellitus.
During physical examination her vital signs were
temperature, 97.1°F; pulse ox 97% on room air;
blood pressure 142/99; pulse rate 97; respirations
18; and Body Mass Index score of 40. Her orophar-
ynx was clear and revealed no edema of the tongue
or soft palate and there were no tonsillar exudates
or ulcerations. There was marked tense edema of
the upper lip extending to the lower portion of the
nose and obliterating the contour of the nasolabial
folds. The lower lip was normal in appearance
without edema. Her lungs were clear to ausculta-
tion and without wheezing or stridor. She did not
have a rash or any other signs of systemic allergic
reaction. White blood cell count with differential
and sedimentation rate were normal. Urine preg-
nancy test was negative.
In the emergency department she received epi-
nephrine (1:1000) 0.3 mL intramuscular once,
methylprednisolone 125 mg intravenous once, and
diphenhydramine 50 mg intravenous once. She was
admitted to the family medicine service for obser-
vation and monitoring of her airway, and lisinopril
was discontinued. By day 2 of her hospital stay, the
angioedema had resolved, her sensation of chest
and throat tightness was gone, and she was dis-
charged from the hospital on an oral prednisone
taper. She was instructed to permanently discon-
tinue all drugs in the ACE inhibitor class and an-
giotensin receptor blocker class. On the day of
discharge, her blood pressure was 128/70 on only
hydrochlorothiazide. Further adjustments to her
hypertensive medication regimen were deferred to
her outpatient follow-up, which was scheduled
within 1 week.
Discussion
The preceding case represents ACE inhibitor-in-
duced angioedema. The patient did not have any
allergic symptoms such as urticaria, which makes
allergic angioedema unlikely. Other causes of an-
gioedema include hereditary angioedema, preg-
nancy, lymphoproliferative malignancies, and in-
fection. Given this patient’s age of presentation,
normal laboratory results, and lack of supportive
history or physical ﬁndings, these alternate etiolo-
gies are very unlikely. Other medications should be
considered as a precipitant. However, of this pa-
tient’s medicine list, lisinopril was the most likely
cause and her symptoms resolved after discontinu-
ation whereas hydrochlorothiazide was continued,
establishing our diagnosis of ACE inhibitor-in-
duced angioedema.
Multiple case reports have related direct injury
caused by perioperative trauma (intubation, oral sur-
gery, anterior dissection of the neck for carotid end-
arectomy, or cervical laminectomy, etc) as the inciting
factor in ACE inhibitor-related angioedema.5–7 In
this patient the angioedema was conﬁned to the upper
lip and its presentation coincided with direct trauma
to her upper lip, making trauma a likely precipitant. A
MEDLINE search conducted in January 2007 was
unable to ﬁnd another case report describing a spe-
ciﬁc cause and effect phenomenon related to nonsur-
gical trauma. The authors hypothesize that the injury
caused by biting her upper lip set off a cascade of local
events leading to ACE inhibitor-related angioedema.
Bradykinin is a vasoactive peptide causing vaso-
dilatation and increased vascular permeability, and
is 10 times more potent than histamine.2,8 High
levels of circulating bradykinin have been well doc-
umented in patients with angioedema.4 Although
multiple vasoactive peptides have been implicated
in angioedema, including substance P,1 bradykinin
is arguably the most important in ACE inhibitor-
related angioedema. Half of the patients found to
Figure 1. Angiodema confined to the upper lip.
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have ACE inhibitor-related angioedema have a de-
fect in bradykinin metabolism. Similarly, the 4-fold
increase in angioedema found in African-American
patients is felt to be secondary to genetic differ-
ences in the kallikrein–kinin system.4
Acute trauma causes activation of bradykinin
through the release of factor XII of the clotting
cascade.2 Bradykinin is then broken down by ACE
while passing through the lung.3 The blockade of
this enzyme by ACE inhibitor leads to both the
local and systemic accumulation of bradykinin in
susceptible individuals by decreasing its catabolism.
The aforementioned surgical trauma cases re-
sulting in angioedema ascribed this phenomenon to
the synergistic effect of increased bradykinin lev-
els.5–7 In this patient, the authors postulate that the
causative agent was local self-induced trauma to the
patient’s upper lip. Her lower lip was spared the
trauma and hence was entirely free of angioedema.
Her shortness of breath during the initial presen-
tation illustrates the systemic nature of angio-
edema, resulting from higher serum levels of bra-
dykinin.
Conclusion
This case underscores the fact that everyday trauma
such as casually biting one’s lip can be enough of a
catalyst to cause severe ACE inhibitor-related an-
gioedema in susceptible individuals. This mecha-
nism of accidental self-induced injury is often over-
looked in everyday practice. The authors propose
that patients on ACE inhibitors should be warned
that local trauma has the potential to precipitate
severe angioedema. Patients should be advised to
report any such instances to their primary care
doctor for discussion. Failure to do so could have
disastrous consequences, including death from con-
tinued administration of the offending agent. This
point was emphasized in the recent report of the
experience with angioedema in the Antihyperten-
sive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial.9 However, the ultimate treat-
ment for ACE inhibitor-related angioedema is the
same regardless of the cause: permanent discontin-
uation of all ACE inhibitors. Finally, angiotensin
receptor blockers should be used with caution in
patients with ACE inhibitor-induced angioedema.
Angiotensin receptor blocker therapy has also been
shown to increase bradykinin levels.10 Patients who
have had ACE inhibitor-induced angioedema are at
increased risk to develop angiotensin receptor
blocker-induced angioedema; however, the abso-
lute risk is still quite small.11 Angiotensin receptor
blocker therapy is a reasonable alternative, but the
decision to use it should be made by both the
patient and the physician after a full discussion of
risks and beneﬁts.
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